Novartis' multiple sclerosis drug Gilenya garners Russian approval

Novartis' once-daily oral drug Gilenya (fingolimod) received its first marketing approval after Russian regulators cleared the product for the treatment of relapsing remitting multiple sclerosis. The Swiss drugmaker expects to launch Gilenya in Russia in early 2011. In the US, where the drug is known as Gilenia, an advisory panel recommended approval of the product in June, with a final decision from the FDA anticipated later this month.
Reference Articles
Novartis announces Russian regulatory approval for Gilenya, a once-daily oral multiple sclerosis therapy and first in a new class - (Novartis)
Novartis' Gilenya receives Russian regulatory approval - (Stock Markets Review)
Russia becomes first to approve Novartis drug Gilenya (free preview) - (The Wall Street Journal)
**Published in "FW Pharma"